180 Life Sciences Corp (ATNF)
1.585
-0.06
(-3.94%)
USD |
NASDAQ |
May 17, 16:00
1.585
0.00 (0.00%)
After-Hours: 20:00
180 Life Sciences Research and Development Expense (Quarterly): -0.0364M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0364M |
| September 30, 2023 | 1.105M |
| June 30, 2023 | 0.9209M |
| March 31, 2023 | 0.795M |
| December 31, 2022 | 0.5857M |
| September 30, 2022 | 0.6365M |
| June 30, 2022 | 0.5037M |
| March 31, 2022 | 0.7067M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.972M |
| September 30, 2021 | 0.6154M |
| June 30, 2021 | 0.9945M |
| March 31, 2021 | 0.367M |
| December 31, 2020 | 0.8589M |
| September 30, 2020 | 0.4996M |
| June 30, 2020 | 0.4311M |
| March 31, 2020 | 0.5035M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-0.0364M
Minimum
Dec 2023
1.972M
Maximum
Dec 2021
0.7162M
Average
0.6259M
Median
Research and Development Expense (Quarterly) Benchmarks
| Altimmune Inc | 21.49M |
| Seelos Therapeutics Inc | 3.525M |
| GT Biopharma Inc | 1.357M |
| Outlook Therapeutics Inc | 13.51M |
| MAIA Biotechnology Inc | 2.321M |